OBJECTIVE: To investigate the medium- and long-term outcomes of multisession cyberknife radiosurgery intreating cavernous @entity50 (CSH). METHODS: Between January 2008 and February 2012, 45 @entity1 with CSH, including 35 female and 10 male @entity1 with a mean age of 53 years (range: 26-80 years), underwent multisession cyberknife radiosurgery. The mean diameter of the CSH was 47.0 mm (range: 23.0-75.0 mm). The @entity5 volume ranged from 2.9 to 140.1 cm(3), with a mean of 40.1 cm(3). Eleven giant CSH with @entity5 volume >=  40.0 cm(3) were irradiated by cyberknife in 4 fractions, 28 large @entity5 with @entity5 volume 10.0-40.0 cm(3) in 3 fractions, 4 @entity5 with @entity5 volume 5.0-10.0 cm(3) in 2 fractions, 2 small @entity5 with @entity5 volume  <= 5.0 cm(3) in 1 fraction. After the treatment, all @entity1 had regular clinical and radiological follow-up at 6-month intervals. A combination of the neurologic examination and MRI information was used to evaluate the overall response. RESULTS: All @entity1 were followed up for 22-70 months with a mean of 37.7 months. One @entity1 died of @entity64 3 years post cyberknife, but the follow-up MRI showed that the CSH shrank in volume. Eight @entity1 with giant CSH had slight @entity10 after finishing cyberknife radiosurgery, and relieved with @entity2656 and @entity619 treatment. @entity51 in @entity1 had improved or disappeared at 6 to 12 months post cyberknife. None of these @entity1 showed any deterioration in symptoms or new @entity129 during the follow-up. Latest follow-up imaging demonstrated that @entity5 decrease > 80% in 15 @entity1 , > 60% to 80% in 18 @entity1 (including the @entity204 @entity1 ), 40%-60% in 12 @entity1 post cyberknife. Two @entity1 reported occurrence of @entity410 and maintaining @entity410 control after antiepileptic drugs administration. CONCLUSIONS: Multisession cyberknife radiosurgery is confirmed to provide medium and long-term @entity5 control and symptom improvement. It is a safe and effective treatment modality for CSH, and may serve as a promising treatment option in the future.

[Multisession cyberknife radiosurgery for cavernous XXXX : medium- and long-term outcomes].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2656 :: ('MESH:D008353', 'Chemical') :: ['mannitol'] @entity129 :: ('MESH:D003389', 'Disease') :: ['cranial nerve deficits'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'local tumor', 'tumors'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity51 :: ('MESH:D009461', 'Disease') :: ['Neurological deficits'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity50 :: ('MESH:D012851', 'Disease') :: ['sinus hemangiomas']
@entity50 :: (MESH:D012851,Disease) :: ['sinus hemangiomas']
